Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A2 | P11168 | 7/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | TSPO | P30536 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1691676 | 0.94 | SLC2A2 (0.49) | SLC2A2SLC2A1ALDH1A1NR1I2ABCB11 | |
| SCHEMBL17718968 | 0.83 | SLC2A1 (0.75) | SLC2A2SLC2A1 | |
| SCHEMBL1691241 | 0.81 | ALDH1A1 (0.68) | SLC2A1ALDH1A1NR1I2ABCB11ALB | |
| SCHEMBL1691320 | 0.79 | SLC2A1 (0.56) | SLC2A2SLC2A1ALDH1A1NR1I2ABCB11 | |
| SCHEMBL1691342 | 0.79 | SLC2A1 (0.56) | SLC2A2SLC2A1ALDH1A1NR1I2ABCB11 | |
| SCHEMBL1691376 | 0.79 | ALDH1A1 (0.58) | SLC2A2SLC2A1ALDH1A1NR1I2ABCB11 | |
| Bromide SCHEMBL1691362 | 0.78 | SLC2A1 (0.56) | SLC2A2SLC2A1ALDH1A1NR1I2ABCB11 | |
| SCHEMBL10175208 | 0.78 | GABRA2 (0.53) | SLC2A2SLC2A1ALDH1A1NR1I2ABCB11 | |
| SCHEMBL14632132 | 0.78 | MCHR1 (0.42) | SLC2A2SLC2A1ALBOPRK1KCNH2 | |
| SCHEMBL1691321 | 0.77 | ALDH1A1 (0.56) | SLC2A2SLC2A1ALDH1A1NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | claimed |
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | BIOVITRUM AB (PUBL) (SE) | 2015-08-27 | — | — | US | claimed |
| EP-2376490-B1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD (GB) | 2013-01-23 | — | — | EP | claimed |
| US-20120010188-A1 | Imidazopyridine Compounds | PROMIMAGEN LTD. (GB) | 2012-01-12 | — | — | US | claimed |
| EP-2376490-A1 | IMIDAZOPYRIDINE COMPOUNDS | Proximagen Limited (GB) | 2011-10-19 | — | — | EP | claimed |
| WO-2010064020-A1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD. (GB) | 2010-06-10 | — | — | WO | claimed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| WO-2017098236-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | PROXIMAGEN LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| WO-2015189534-A1 | VAP-1 INHIBITORS FOR TREATING MUSCULAR DYSTROPHY | PROXIMAGEN LIMITED (GB) | 2015-12-17 | — | — | WO | disclosed |
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | BIOVITRUM AB (PUBL) (SE) | 2015-08-27 | — | — | US | disclosed |
| EP-2376490-B1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| EP-2376490-B1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-20120010188-A1 | Imidazopyridine Compounds | PROMIMAGEN LTD. (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010188-A1 | Imidazopyridine Compounds | PROMIMAGEN LTD. (GB) | 2012-01-12 | — | — | US | disclosed |
| EP-2376490-A1 | IMIDAZOPYRIDINE COMPOUNDS | Proximagen Limited (GB) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010064020-A1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD. (GB) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010064020-A1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD. (GB) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | SLC2A2 3604/4885SLC2A1 2866/4885ALDH1A1 477/4885 |
| US-20120010188-A1 | Imidazopyridine Compounds | SSB, MIF, IDO1 | SLC2A2 1914/4885SLC2A1 1801/4885ALDH1A1 65/4885 |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, AOX1 | SLC2A2 2278/4885SLC2A1 1772/4885ALDH1A1 289/4885 |
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | SSB, MIF, IDO1 | SLC2A2 1914/4885SLC2A1 1801/4885ALDH1A1 65/4885 |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | VAPB, VAPA, AOX1 | SLC2A2 2262/4885SLC2A1 1743/4885ALDH1A1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.